全文获取类型
收费全文 | 3148篇 |
免费 | 271篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 147篇 |
妇产科学 | 63篇 |
基础医学 | 426篇 |
口腔科学 | 130篇 |
临床医学 | 403篇 |
内科学 | 746篇 |
皮肤病学 | 38篇 |
神经病学 | 161篇 |
特种医学 | 347篇 |
外科学 | 386篇 |
综合类 | 34篇 |
预防医学 | 200篇 |
眼科学 | 22篇 |
药学 | 141篇 |
中国医学 | 6篇 |
肿瘤学 | 168篇 |
出版年
2021年 | 32篇 |
2020年 | 34篇 |
2019年 | 45篇 |
2018年 | 54篇 |
2017年 | 41篇 |
2016年 | 43篇 |
2015年 | 56篇 |
2014年 | 72篇 |
2013年 | 95篇 |
2012年 | 100篇 |
2011年 | 124篇 |
2010年 | 101篇 |
2009年 | 115篇 |
2008年 | 133篇 |
2007年 | 129篇 |
2006年 | 91篇 |
2005年 | 90篇 |
2004年 | 92篇 |
2003年 | 93篇 |
2002年 | 108篇 |
2001年 | 99篇 |
2000年 | 95篇 |
1999年 | 72篇 |
1998年 | 74篇 |
1997年 | 72篇 |
1996年 | 79篇 |
1995年 | 66篇 |
1994年 | 57篇 |
1993年 | 57篇 |
1992年 | 62篇 |
1991年 | 44篇 |
1990年 | 61篇 |
1989年 | 70篇 |
1988年 | 73篇 |
1987年 | 76篇 |
1986年 | 64篇 |
1985年 | 68篇 |
1984年 | 40篇 |
1983年 | 30篇 |
1982年 | 36篇 |
1981年 | 30篇 |
1979年 | 32篇 |
1978年 | 27篇 |
1977年 | 31篇 |
1976年 | 26篇 |
1975年 | 43篇 |
1974年 | 30篇 |
1973年 | 35篇 |
1972年 | 28篇 |
1971年 | 24篇 |
排序方式: 共有3433条查询结果,搜索用时 78 毫秒
1.
Renaud Snanoudj Nassim Kamar Elisabeth Cassuto Sophie Caillard Marie Metzger Pierre Merville Antoine Thierry Isabelle Jollet Philippe Grimbert Dany Anglicheau Marc Hazzan Gabriel Choukroun Bruno Hurault De Ligny Bénedicte Janbon Vincent Vuiblet Anne Devys Yann Le Meur Michel Delahousse Jean-Luc Taupin 《Kidney international》2019,95(6):1471-1485
2.
J.L. Bernat A.M. D'Alessandro F.K. Port T.P. Bleck S.O. Heard J. Medina S.H. Rosenbaum M.A. DeVita R.S. Gaston R.M. Merion M.L. Barr W.H. Marks H. Nathan K. O'Connor D.L. Rudow A.B. Leichtman P. Schwab N.L. Ascher R.A. Metzger V. Mc Bride W. Graham D. Wagner J. Warren F.L. Delmonico 《American journal of transplantation》2006,6(2):281-291
A national conference on organ donation after cardiac death (DCD) was convened to expand the practice of DCD in the continuum of quality end-of-life care. This national conference affirmed the ethical propriety of DCD as not violating the dead donor rule. Further, by new developments not previously reported, the conference resolved controversy regarding the period of circulatory cessation that determines death and allows administration of pre-recovery pharmacologic agents, it established conditions of DCD eligibility, it presented current data regarding the successful transplantation of organs from DCD, it proposed a new framework of data reporting regarding ischemic events, it made specific recommendations to agencies and organizations to remove barriers to DCD, it brought guidance regarding organ allocation and the process of informed consent and it set an action plan to address media issues. When a consensual decision is made to withdraw life support by the attending physician and patient or by the attending physician and a family member or surrogate (particularly in an intensive care unit), a routine opportunity for DCD should be available to honor the deceased donor's wishes in every donor service area (DSA) of the United States. 相似文献
3.
4.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
5.
6.
7.
D Machover E Goldschmidt P Chollet G Metzger J Zittoun M Benavides J Marquet J M Vandenbulcke J L Misset L Schwarzenberg 《NCI monographs : a publication of the National Cancer Institute》1987,(5):193-198
We report the results of an expanded trial of 5-fluorouracil (FUra) combined with high-dose folinic acid for treatment of patients with advanced colorectal or gastric adenocarcinoma. In each treatment course, the patients received both FUra (340-400 mg/m2/day by iv infusion over 15 minutes) and folinic acid (200 mg/m2/day by iv bolus) for 5 consecutive days, with a 21-day interval between courses. Eighty-six patients with colorectal carcinoma were evaluated. The combined complete response (CR) and partial response (PR) rates were 39% for 54 patients who did not receive prior chemotherapy and 22% for 32 patients who had previously received chemotherapy. Four patients who were previously resistant to FUra attained objective responses. The median time to disease progression for the 28 responders was 10 months. The median survival time of responders was 19.5 months, and the probability of their being alive at 2 years was 40%. Of 27 patients with gastric adenocarcinoma, 13 (48%) responded to therapy. Their median time to disease progression was 5.5 months. The median survival time of responders was 11 months, and their probability of being alive at 15 months was 30%. Toxicity was within acceptable limits. Toxic effects included stomatitis, diarrhea, conjunctivitis, skin rash, and mild myeloid hypoplasia. In a separate study, plasma concentrations of L-folates above 10(-5) M were achieved after a rapid single iv injection of 200 mg/m2 of folinic acid.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
8.
We have investigated the activation of mouse peritoneal macrophages by injection of aclacinomycin (ACM). Macrophages from ACM-treated mice have an increased phagocytic activity as measured by Candida ingestion. The microbicidal activity indirectly evaluated by chemiluminescence and superoxide determination in response to stimulation with zymosan and 4 beta-phorbol-12-myristate-13 alpha-acetate is also greater in the cells from treated mice. Direct measurement of the cytostatic function, and of in vitro and in vivo cytotoxicity shows comparable significant increases against L1210 or P815 target cells. The enhanced antitumoral activity could not be attributed to the residual presence of ACM in the peritoneal cells since no drug was detected by high-performance liquid chromatography and since their freeze-thaw lysates incubated with P815 cells did not modify the growth of tumor cells as measured by [3H]-thymidine incorporation. We also checked that the presence of ACM did not influence the intensity of the chemiluminescence. In all tests performed, only i.p. ACM administration could stimulate the peritoneal cells. Since the doses of ACM inducing an increase in macrophage activity are effective on the survival of tumor-bearing mice, the participation of this mechanism in tumor control might be suggested. 相似文献
9.